Abstract
Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months. Randomized ciné film of the patients' involuntary movements, taken before, during, and after treatment was assessed individually by seven `blind' observers. Eight patients were judged improved; two had Huntington's chorea, two athetosis, two dystonia musculorum deformans, one hemiballismus, and one spasmodic torticollis. Four of the eight improved patients have continued taking the drug for longer than six months. In a second study seven patients with Huntington's chorea were treated for two weeks each with tetrabenazine (50 mg t.d.s.) and with amantadine (100 mg t.d.s.) and the results assessed by the same method. The choreiform movements of six of these patients were strikingly improved with tetrabenazine therapy, but amantadine had no effect. Tetrabenazine is an effective agent for the suppression of choreiform and ballistic involuntary movements. It is only slightly effective in the treatment of athetosis and spasmodic torticollis. Drowsiness, insomnia, and depression were the most conspicuous unwanted effects, and these may limit the clinical usefulness of the drug.
Full text
PDF![186](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/e442269f6af0/jnnpsyc00206-0039.png)
![187](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/2c82f6f5088a/jnnpsyc00206-0040.png)
![188](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/67a64f7a13d5/jnnpsyc00206-0041.png)
![189](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/2595160395ca/jnnpsyc00206-0042.png)
![190](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/b631d435fc46/jnnpsyc00206-0043.png)
![191](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bf6/494034/af1a6120cda1/jnnpsyc00206-0044.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ASHCROFT G. W., MACDOUGALL E. J., BARKER P. A. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci. 1961 Mar;107:287–293. doi: 10.1192/bjp.107.447.287. [DOI] [PubMed] [Google Scholar]
- BRANDRUP E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961 Dec;118:551–552. doi: 10.1176/ajp.118.6.551. [DOI] [PubMed] [Google Scholar]
- Calne D. B., Sandler M. L-Dopa and Parkinsonism. Nature. 1970 Apr 4;226(5240):21–24. doi: 10.1038/226021a0. [DOI] [PubMed] [Google Scholar]
- Dalby M. A. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J. 1969 May 17;2(5654):422–423. doi: 10.1136/bmj.2.5654.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FORREST A. D. Some observations on Huntington's chorea. J Ment Sci. 1957 Jul;103(432):507–513. doi: 10.1192/bjp.103.432.507. [DOI] [PubMed] [Google Scholar]
- Klawans H. C., Paulson G. W., Barbeau A. Predictive test for Huntington's chorea. Lancet. 1970 Dec 5;2(7684):1185–1186. doi: 10.1016/s0140-6736(70)90367-3. [DOI] [PubMed] [Google Scholar]
- MacCallum W. A. Tetrabenazine for extra-pyramidal movement disorders. Br Med J. 1970 Mar 21;1(5698):760–760. doi: 10.1136/bmj.1.5698.760-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand. 1968;44(3):391–393. doi: 10.1111/j.1600-0404.1968.tb05581.x. [DOI] [PubMed] [Google Scholar]
- SATTES H. [The treatment of chorea minor with the monoamine liberator "Nitoman"]. Psychiatr Neurol (Basel) 1960 Jul;140:13–19. [PubMed] [Google Scholar]
- Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]